The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy

Inclusion Criteria:

• Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
• Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.

Exclusion Criteria:

• Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1).
• Those who are expected to need insulin prescription during the study period.

Patients with type 2 diabetes scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone